Hyperkalaemia in the age of aldosterone antagonism

Chapagain, A.; Ashman, N.
November 2012
QJM: An International Journal of Medicine;Nov2012, Vol. 105 Issue 11, p1049
Academic Journal
Hyperkalaemia is well recognized as a medical emergency. However, with the publication of trials showing benefit with renin-aldosterone axis suppression in heart failure, the epidemiology of patients presenting with hyperkalaemia has changed. The reported incidence of rate of serious hyperkalaemia (>6.0 mEq/l of potassium) ranges from 6 to 12% in patients on spironolactone with congestive cardiac failure (CCF). A rational choice of therapy based on present evidence is different from the traditionally used algorithm, given our understanding of the physiology relevant to this patient group. This article discusses the changing face of hyperkalaemia and the present evidence and discusses options in treatment of hyperkalaemia.


Related Articles

  • Aldosterone antagonists in heart failure with reduced ejection fraction. O'Donovan, Kate // Nurse Prescribing;2015, Vol. 13 Issue 5, p242 

    Heart failure with reduced ejection fraction is associated with increased mortality, limited functional capacity and poor quality of life. The renin--angiotensin--aldosterone system (RAAS) is an essential compensatory mechanism that attempts to maintain organ perfusion. The secretion of...

  • The Risks and Benefits of Therapy with Aldosterone Receptor Antagonist Therapy. Sica, Domenic A. // Current Drug Safety;Jan2007, Vol. 2 Issue 1, p71 

    Spironolacotone and eplerenone are mineralocorticoid-blocking agents. These compounds block both the epithelial and non-epithelial actions of aldosterone with the latter assuming increasing clinical importance. Spironolactone and eplerenone both effectively reduce blood pressure either as mono-...

  • Aldactide 50.  // Royal Society of Medicine: Medicines;2002, p42 

    The article presents information on Aldactide 50, a proprietary, prescription-only compound preparation of the aldosterone-antagonist and potassium-sparing spironolactone and the thiazide-type diuretic hydroflumethiazide. This drug can be used for heart failure treatment and is available as tablets.

  • Aldosterone Antagonists � Last Man Standing? Armstrong, Paul W. // New England Journal of Medicine;1/6/2011, Vol. 364 Issue 1, p79 

    The author reflects on aldosterone antagonists in the treatment of heart failure. It says that in the turn of the millennium, there are four cardiac medicines developed before 1960 that survived namely aspirin, digoxin, warfarin and spironolactone. It highlights two studies whose findings have...

  • Spironolactone.  // Reactions Weekly;3/10/2007, Issue 1142, p21 

    The article presents a case report of a man with congestive heart failure and was receiving spironolactone daily. It states that a condition called gynecomastia which is an increasing breast size in the patient during his treatment made his medication replaced by eplerenone. The author mentions...

  • Aldosterone Antagonists: The Most Underutilized Class of Heart Failure Medications. Guglin, Maya; Awad, Khaled Esmaeel; Polavaram, Latha; Vankayala, Hema // American Journal of Cardiovascular Drugs;2007, Vol. 7 Issue 1, p75 

    BACKGROUND: Aldosterone antagonists have been proven to be beneficial in severe heart failure (HF) as a result of systolic dysfunction. We sought to determine if there is a disparity in their utilization compared with ACE inhibitors and β-adrenoceptor antagonists (β-blockers). METHODS:...

  • Eplerenone Use for Mild Symptomatic Heart Failure? Crawford, Michael H. // Clinical Cardiology Alert;Mar2011, Vol. 30 Issue 3, p17 

    In this article the author questions the use of eplerenone as an alternative to spironolactone in systolic heart failure (HF) patients with mild symptoms, by referencing a study by F. Zannad and colleagues. He presents details related to the study, and opines that its unique features have...

  • Early Spironolactone Treatment Attenuates Heart Failure Development by Improving Myocardial Function and Reducing Fibrosis in Spontaneously Hypertensive Rats. Cezar, Marcelo D.M.; Damatto, Ricardo L.; Pagan, Luana U.; Lima, aline R.R.; Martinez, Paula F.; Bonomo, Camila; Rosa, Camila M.; Campos, Dijon H.S.; Cicogna, antonio C.; Gomes, Mariana J.; Oliveira-Jr, Silvio a.; Blotta, Daniella a.; Okoshi, Marina P.; Okoshi, Katashi // Cellular Physiology & Biochemistry (Karger AG);Jul2015, Vol. 36 Issue 4, p1453 

    Background: We evaluated the role of the aldosterone blocker spironolactone in attenuating long-term pressure overload-induced cardiac remodeling and heart failure (HF) in spontaneously hypertensive rats (SHR). Methods and Results: Thirteen month-old male SHR were assigned to control (SHR-C,...

  • Role of the Renin-Angiotensin-Aldosterone System in Diastolic Heart Failure: Potential for Pharmacologic Intervention. Bernal, Juan; Pitta, Sridevi R.; Thatai, Deepak // American Journal of Cardiovascular Drugs;2006, Vol. 6 Issue 6, p373 

    Congestive heart failure (CHF) is a major public health problem that results in tremendous economic burden. Diastolic heart failure (DHF) forms an important subset with increasing incidence and prevalence. There are widely variable estimates of the prevalence, ranging from 13% to 74% of all...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics